Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
The protein encoded by Slc7a7 is the light subunit of a cationic amino acid transporter. De plus, nous expédions Solute Carrier Family 7 (Amino Acid Transporter Light Chain, Y+L System), Member 7 Kits (16) et Solute Carrier Family 7 (Amino Acid Transporter Light Chain, Y+L System), Member 7 Protéines (4) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 13 products:
Human Polyclonal Slc7a7 Primary Antibody pour WB - ABIN522495
Barilli, Rotoli, Visigalli, Bussolati, Gazzola, DallAsta: Arginine transport in human monocytic leukemia THP-1 cells during macrophage differentiation. dans Journal of leukocyte biology 2011
heteromerization of y+LAT1 and 4F2hc (Montrer SLC3A2 Anticorps) within the cell is not disrupted by any of the tested LPI mutations
SLC7A7 genetic variants are associated with increase risk for glioma in a Chinese population.
SLC7A7 plays a critical role in glioblastoma carcinogenesis and overexpression of SLC7A7 is correlated with worse outcomes in patients
SLC7A7/y+LAT1 mutations lead to a defective phenotype of macrophages resulting in lysinuric Protein Intolerance.
during differentiation of human monocytes from peripheral blood, SLC7A7 mRNA and system y(+)L activity are increased
novel SLC7A7 mutations in patients with lysinuric protein intolerance
expression levels and putative 5' promoter elements of the SLC7A7 gene
putative multiheteromeric structure of both [4F2hc (Montrer SLC3A2 Anticorps)/y(+)LAT-1] and [4F2hc (Montrer SLC3A2 Anticorps)/y(+)LAT-2 (Montrer SLC7A6 Anticorps)], and the interference between y(+)LAT-1 and y(+)LAT-2 (Montrer SLC7A6 Anticorps) proteins may have a role in the pathogenesis of lysinuric protein intolerance
mutations of the SLC7A7 gene may have a role in lysinuric protein intolerance
identified a novel alternative, TATA-box-containing promoter that plays a role in the tissue-specific regulation of SLC7A7 gene expression
The expression of Mct8 (Montrer MCT8 Anticorps) and L-type amino acid transporters Lat2 (Montrer SLC7A8 Anticorps) and Lat1 (Montrer SLC7A5 Anticorps) are determined in brain neurons during development.
Increased LAT1 (Montrer SLC7A5 Anticorps) expression can be induced by lipid oxidation products relevant to inflammatory responses in atherogenesis. LAT1 (Montrer SLC7A5 Anticorps) mediates lysophosphatidylcholine-enhanced cytokine production by endothelial cells.
selective regulation of SNAT3 (Montrer SLC38A3 Anticorps) and y(+)LAT1 expression may serve a major role in the renal adaptation to acid secretion and thus for systemic acid-base balance.
The Slc7a7(-/-) mouse displayed intrauterine growth restriction, leading to neonatal lethality. After heavy protein ingestion, the surviving adult animals presented metabolic derangement consistent with lysinuric protein intolerance.
LAT1 (Montrer SLC7A5 Anticorps), and LAT2 (Montrer SLC7A8 Anticorps) mRNAs were detected in fetal and postnatal femurs and in MC3T3-E1 cells, while OATP1 (Montrer Slco1a1 Anticorps) and NTCP (Montrer SLC10A1 Anticorps) mRNAs were not.
The protein encoded by this gene is the light subunit of a cationic amino acid transporter. This sodium-independent transporter is formed when the light subunit encoded by this gene dimerizes with the heavy subunit transporter protein SLC3A2. This transporter is found in epithelial cell membranes where it transfers cationic and large neutral amino acids from the cell to the extracellular space. Defects in this gene are a cause of lysinuric protein intolerance (LPI). Alternative splicing results in multiple transcript variants.
Y+L amino acid transporter 1
, monocyte amino acid permease 2
, solute carrier family 7 (cationic amino acid transporter, y+ system), member 7
, y(+)L-type amino acid transporter 1
, solute carrier family 7 member 7